SCHEMBL14549596

SCHEMBL14549596

c1ccc(-c2nn[nH]n2)nc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 1.00
TP53 P04637 2/20 0.59
L3MBTL1 Q9Y468 3/20 0.55
ALDH1A1 P00352 2/20 0.55
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
TDP1 Q9NUW8 2/20 0.54
HSD17B10 Q99714 3/20 0.50
LMNA P02545 2/20 0.50
NPC1 O15118 2/20 0.50
PKM P14618 2/20 0.50
ALOX15 P16050 2/20 0.50
RAB9A P51151 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
CYP1A2 P05177 1/20 0.50
POLB P06746 1/20 0.50
CCR1 P32246 1/20 0.50
CCR5 P51681 1/20 0.50
CCR8 P51685 1/20 0.50
METAP1 P53582 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2202808 0.88 KDM4E (0.77) KDM4ETP53L3MBTL1ALDH1A1MEN1
SCHEMBL2200277 0.88 KDM4E (0.77) KDM4ETP53L3MBTL1ALDH1A1MEN1
SCHEMBL31324840 0.76 KDM4E (0.61) KDM4EL3MBTL1ALDH1A1MEN1KMT2A
SCHEMBL29767699 0.75 TP53 (1.00) KDM4ETP53L3MBTL1ALDH1A1TDP1
SCHEMBL30694104 0.75 TP53 (1.00) KDM4ETP53L3MBTL1ALDH1A1TDP1
SCHEMBL2852298 0.75 TP53 (1.00) KDM4ETP53L3MBTL1ALDH1A1TDP1
SCHEMBL31268013 0.73 KDM4E (0.75) KDM4ETP53L3MBTL1ALDH1A1TDP1
SCHEMBL580823 0.73 KDM4E (0.75) KDM4ETP53L3MBTL1ALDH1A1TDP1
SCHEMBL322756 0.71 KDM4E (1.00) KDM4ETP53L3MBTL1ALDH1A1TDP1
SCHEMBL29354466 0.71 KDM4E (1.00) KDM4ETP53L3MBTL1ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368131-A1 OXOINDOLINYL AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF VENTUS THERAPEUTICS U S INC (US) 2024-11-07 US disclosed
EP-4192831-A1 HETEROCYCLIC GLP-1 AGONISTS Gasherbrum Bio, Inc. (US) 2023-06-14 EP disclosed
CN-107208279-B Etching solution, replenishment solution, and method for forming copper wiring MEC股份有限公司 2021-03-26 CN disclosed
US-10273222-B2 Histone demethylase inhibitors CELGENE QUANTSCEL RESEARCH, INC. (US) 2019-04-30 US disclosed
US-10174428-B2 Etchant, replenishment solution and method for forming copper wiring MEC COMPANY LTD. (JP) 2019-01-08 US disclosed
US-10028992-B2 Methods of treating muscular dystrophy BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) 2018-07-24 US disclosed
US-10028992-B2 Methods of treating muscular dystrophy BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) 2018-07-24 US disclosed
EP-2892525-B1 METHODS OF TREATING MUSCULAR DYSTROPHY UNIV NEVADA RENO (US) 2018-06-13 EP disclosed
US-9963441-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2018-05-08 US disclosed
US-20170334879-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RES INC (US) 2017-11-23 US disclosed
US-20150290276-A1 METHODS OF TREATING MUSCULAR DYSTROPHY BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY 2015-10-15 US disclosed
US-20150290276-A1 METHODS OF TREATING MUSCULAR DYSTROPHY BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY 2015-10-15 US disclosed
US-9133166-B2 Histone demethylase inhibitors Quanticel Pharmaceuticals, Inc. (US) 2015-09-15 US disclosed
EP-2543631-B1 Method for preparing metal-free nitrogen-containing carbon nanotubes COMMISSARIAT L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2014-10-01 EP disclosed
US-20140275084-A1 HISTONE DEMETHYLASE INHIBITORS Quanticel Pharmaceuticals, Inc. (US) 2014-09-18 US disclosed
CN-102272262-B Novel compound for organic photoelectric device and organic photoelectric device comprising same CHEIL IND INC 2014-09-10 CN disclosed
CN-101802129-B Novel compound for organic photoelectric device and organic photoelectric device including the same CHEIL WOOL TEXTILE CO LTD 2014-01-01 CN disclosed
WO-2013005187-A1 METHOD FOR PREPARING METAL-FREE NITROGEN-CONTAINING CARBON NANOTUBES COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2013-01-10 WO disclosed
EP-2543631-A1 Method for preparing metal-free nitrogen-containing carbon nanotubes Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) 2013-01-09 EP disclosed
CN-102272262-A Novel compound for organic photoelectric device and organic photoelectric device comprising same 2011-12-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150290276-A1 METHODS OF TREATING MUSCULAR DYSTROPHY ITGB7, ITGA2B, ITGB1 KDM4E 3012/4885TP53 4875/4885L3MBTL1 1685/4885
US-10273222-B2 Histone demethylase inhibitors KDM1B, KDM1A, KDM3B KDM4E 16/4885TP53 304/4885L3MBTL1 972/4885
US-10028992-B2 Methods of treating muscular dystrophy ITGB7, ITGA2B, ITGB1 KDM4E 3012/4885TP53 4875/4885L3MBTL1 1685/4885
US-20170334879-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, KDM3B KDM4E 16/4885TP53 304/4885L3MBTL1 972/4885
US-20140275084-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, KDM3B KDM4E 16/4885TP53 304/4885L3MBTL1 972/4885
US-20240368131-A1 OXOINDOLINYL AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF NLRP3, NLRP1, NOD1 KDM4E 4532/4885TP53 360/4885L3MBTL1 2986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.